Drugs / BUDIODARONE
BUDIODARONE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00389792 Comparator | Jul 2006 → Dec 2008 | atrial fibrillation | ARYx Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BUDIODARONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105631 ↗ |
| Known as | ATI-2042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00389792 ↗ |
| Known as | ATI-2042 TARTRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105631 ↗ |
| Known as | Budiodarona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105631 ↗ |
| Known as | BUDIODARONE TARTRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105631 ↗ |
| Modality | Small molecule | — CHEMBL2105631 ↗ |